Zhong Guo Ji Jin Bao·2025-07-21 01:51Group 1 - The core point of the news is that Kanghua Biotech's controlling shareholder will change to Wankexin Biotech, with the stock resuming trading on July 21 after a five-day suspension [1][3] - Wankexin Biotech will acquire 28.4666 million shares from existing shareholders, representing 21.91% of the total share capital after excluding repurchased shares, at a price of approximately 65.03 yuan per share, totaling about 1.851 billion yuan [3][4] - Following the share transfer, Wankexin Biotech will hold 29.99% of the voting rights in Kanghua Biotech, while the previous controlling shareholder, Wang Zhentao, will retain 8.08% of the shares but delegate voting rights to Wankexin Biotech [4][5] Group 2 - Wankexin Biotech was established on July 8, 2025, with a total investment of 763 million yuan, and is primarily controlled by the Shanghai Biomedical M&A Fund, which holds 80.209% of the partnership shares [6][8] - The Shanghai Biomedical M&A Fund was officially established on March 26, 2025, with a total target management scale of 10 billion yuan, aimed at supporting mergers and acquisitions in the biopharmaceutical industry [8][13] - The fund's partners include notable figures from the biopharmaceutical sector, with connections to various companies and investment backgrounds, indicating a strong network for potential growth and collaboration [10][11]